KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Inventory: 2010-2024

Historic Inventory for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $125.3 million.

  • Pacira BioSciences' Inventory rose 40.96% to $157.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.7 million, marking a year-over-year increase of 40.96%. This contributed to the annual value of $125.3 million for FY2024, which is 20.06% up from last year.
  • Per Pacira BioSciences' latest filing, its Inventory stood at $125.3 million for FY2024, which was up 20.06% from $104.4 million recorded in FY2023.
  • Pacira BioSciences' Inventory's 5-year high stood at $125.3 million during FY2024, with a 5-year trough of $64.7 million in FY2020.
  • Over the past 3 years, Pacira BioSciences' median Inventory value was $104.4 million (recorded in 2023), while the average stood at $108.6 million.
  • In the last 5 years, Pacira BioSciences' Inventory skyrocketed by 52.44% in 2021 and then declined by 2.52% in 2022.
  • Pacira BioSciences' Inventory (Yearly) stood at $64.7 million in 2020, then soared by 52.44% to $98.5 million in 2021, then decreased by 2.52% to $96.1 million in 2022, then rose by 8.63% to $104.4 million in 2023, then grew by 20.06% to $125.3 million in 2024.